September 23, 2015 5:00pm

 

There are too many ongoing P2s without data points.  Gone is confidence and increased uncertainty of trial data has made “our” universe continually vulnerable.

Have you missed me and today’s close updates?  Subscribe: http://www.regmedinvestors.com/user/register

 

I bring fresh perspectives that yield a whole that is greater than the sum of the parts as I convey a spectrum of factors that explain outcomes, analytical principles and analysis without the encumbrance of I-Banking.

 

 

U.S. stocks struggled to climb out of the red Wednesday after a rebound in commodity prices fizzled out and as gloomy data pointed to decelerating growth in China and tepid improvement in the Eurozone’s manufacturing sector.

The NASDAQ closed DOWN -3.98 or -0.08% to 4,742.52 and the DOW was also DOWN -50.58 or -0.31% to 16,279.89.

 

 

A day in the life of the stem, cell and gene therapy RegMed SCGT & RM sector and market:

We've been bouncing around all day with up and down pricing being the basis of the remainder of the month and Q3!

  • The stem, cell, gene therapy and regenerative medicine (SCGT & RM) equities opened negative with an A/DL of 13/24 and 6 flats followed by a negative mid-day A/DL of 16/23 and 4 flat.
  • The 3 pm hour solidified a continuing negative A/DL of 11/31 and 1 flat culminating in close with a negative A/DL of 12/30 and 1 flat. 

The iShares Nasdaq Biotechnology ETF (IBB) fluctuated between gains and losses – all day.

  • The CBOE Volatility Index (.VIX), widely considered the best gauge of fear in the index, traded near 22.

Investors have been steering away from the stem, cell, gene therapy and regenerative medicine (SCGT & RM) equities as they continue to wonder which company might be next victim of inconclusive clinical data or the biggest issue – disregard of investor interest!

 

 

Dosing the sector – 43 Patients:

  • Open: NEGATIVE with 24 decliners, 13 advancers and 6 flats;
  • 1st hour (10:30 am): POSITIVE with 20 decliners, 22 advancers and 1 flat;
  • 2nd hour (11:30 am): NEGATIVE with 24 decliners, 15 advancers and 4 flats;
  • Mid-day (12:30 pm) NEGATIVE with 23 decliners, 16 advancers and 4 flats;
  • 3 pm: NEGATIVE with 31 decliners, 11 advancers and 1 flat;
  • Closing bell: NEGATIVE with 30 decliners, 12 advancers and 1 flat

 

 

Wednesday’s trading indications: 1 hit/ 4 miss:

  • bluebird bio (BLUE) closed DOWN -$6.47 – miss;
  • Capricor (CAPR) closed DOWN -$0.05 – hit;
  • Harvard Apparatus RM (HART) closed DOWN -$0.05 – miss;
  • Intrexon (XON) closed DOWN -$0.60 – miss;
  • Organovo (ONVO) closed DOWN - $0.07 – miss;

 

 

The week’s indexes in review:

  • The iShares Nasdaq Biotechnology ETF (IBB) closed DOWN on Wednesday -2.58 or -0.77% following Tuesday’s decline of  -5.07 or -1.49% after Monday’s decline of -16.29 or – 4.57%;
  • The Russell 2000 (IWM) closed DOWN on Wednesday -0.34 or -0.30% following Tuesday’s decline of -1.75 or -1.52% after Monday’s decline of -0.21 or -0.18%
  • The SPDR SD&P Biotech ETF (XBI) closed DOWN on Wednesday -0.04 or -0.05% following Tuesday’s decline of-1.63 or -2.17% after Monday’s decline of -4.28 or -5.39%;
  • The CBOE Volatility Index (.VIX) closed Wednesday near 22 following Tuesday’s 23.5 after Monday’s below 22

 

 

A comparison of the closing bell patterns of advance/decline lines:

  • Last, Wednesday: 23/19;
  • Thursday: 30/9;
  • Friday: 27/15;
  • Monday: 6/35;
  • Tuesday: 7/33;
  • Today, Wednesday: 12/30

 

 

Who was down – lowest 5?

  • bluebird bio (BLUE) was down -$6.47 to $113.37;
  • Regenxbio (RGNX) -$1.54 to $24.51;
  • Intrexon (XON) -$0.60 to $45.38;
  • Applied Genetic Technology (AGTC) -$0.46 to $13.49;
  • Avalanche (AAVL) closed down -$0.34 to $9.83

 

 

Who was UP?

  • Spark Therapeutics (ONCE) was up +$0.75 to $44.01;
  • Mesoblast ADR (USOTC: MBLTY) +$0.81 to$12.93;
  • Osiris (OSIR) +$0.38 to $19.32;
  • Kite Pharma (KITE) +$0.25 to $61.59;
  • Cellectis ADR (CLLS) was up +$0.16 to $31.68

 

 

Who is flat?

  • MiMedx (MDXG) at $10.35

 

 

 

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities as referred to in this publication.